DAMARIS KIPTOO: Open Payments
NPI 1104667591 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$604 in 13 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $343 · 2025 $604
Food & beverage: $517Education: $87
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 1 | $150 |
| Rigel Pharmaceuticals, Inc. | 1 | $119 |
| Daiichi Sankyo Inc. | 1 | $87 |
| Exelixis Inc. | 2 | $79 |
| AstraZeneca Pharmaceuticals LP | 2 | $48 |
| Celgene Corporation | 1 | $26 |
| Genentech USA, Inc. | 1 | $24 |
| Genmab U.S., Inc. | 1 | $20 |
| ARRAY BIOPHARMA INC | 1 | $19 |
| Incyte Corporation | 1 | $18 |
Products named: BREYANZI, REZLIDHIA, Enhertu, CABOMETYX, REBLOZYL, CALQUENCE, Itovebi, IMFINZI.
Industry payments across NV — which companies pay providers there.
